.

● Live

Customize

You are here

Unichem rises on getting USFDA’s nod for Tramadol Hydrochloride Tablets

  • Aug-13-2019
  • 15 Hrs IST

Unichem Laboratories is currently trading at Rs. 179.05, up by 1.05 points or 0.59% from its previous closing of Rs. 178.00 on the BSE.

The scrip opened at Rs. 178.00 and has touched a high and low of Rs. 180.80 and Rs. 174.35 respectively. So far 3603 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 239.75 on 10-Sep-2018 and a 52 week low of Rs. 158.35 on 31-Jul-2019.

Last one week high and low of the scrip stood at Rs. 180.80 and Rs. 163.75 respectively. The current market cap of the company is Rs. 1256.74 crore.

The promoters holding in the company stood at 50.62%, while Institutions and Non-Institutions held 9.49% and 39.88% respectively.

Unichem Laboratories has received ANDA approval from the United States Food and Drug Administration (USFDA) for Unichem's Tramadol Hydrochloride Tablets USP, 50 mg. to market a generic version of Ultram Tablets, 50 mg, of Janssen Pharmaceuticals, Inc. which are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The Product will be commercialized from the company’s Ghaziabad plant.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.